Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review
Tóm tắt
Từ khóa
Tài liệu tham khảo
1. Silverstein MN, Petitt RM, Solberg LA Jr., Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 318: 1292-1294, 1988.
2. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92: 69-76, 1992.
3. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34: 51-54, 1997.
4. Prieto R, Martĺnez-Sellés M, Fernández-Avilés F. Essential thrombocytemia and acute coronary syndrome: clinical profile and association with other thromboembolic events. Acute Card Care 10: 116-120, 2008.
5. Lin GM, Chao TY, Wang WB. Acute coronary syndromes and anagrelide. Int J Cardiol 117: e17-e19, 2007.
6. Rodriguez-Ziccardi M, Rubio M, Lu M, Greenspan A. Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia. BMJ Case Rep 2018: bcr2017220723, 2018.
8. Proietti R, Rognoni A, Ardizzone F, Maccio S, Santagostino A, Rognoni G. Atypical Takotsubo syndrome during anagrelide therapy. J Cardiovasc Med (Hagerstown) 10: 546-549, 2009.
9. Kanakura Y, Miyakawa Y, Wilde P, Smith J, Achenbach H, Okamoto S. Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia. Int J Hematol 100: 353-360, 2014.
10. Ahluwalia M, Donovan H, Singh N, Butcher L, Erusalimsky JD. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. J Thromb Haemost 8: 2252-2261, 2010.
11. Johnston H, Majewski H, Musgrave IF. Involvement of cyclic nucleotides in prejunctional modulation of noradrenaline release in mouse atria. Br J Pharmacol 91: 773-781, 1987.
12. Birgegård G, Björkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89: 520-527, 2004.
13. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 29: 481-491, 2005.
14. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33-45, 2005.
15. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 121: 1720-1728, 2013.
16. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97: 863-866, 2001.
17. Mazzucconi MG, Redi R, Bernasconi S, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 89: 1306-1313, 2004.
18. Gugliotta L, Tieghi A, Tortorella G, et al. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res 35: 1557-1563, 2011.
19. Tortorella G, Piccin A, Tieghi A, et al. Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. Leuk Res 39: 592-598, 2015.
20. Birgegård G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study. Haematologica 103: 51-60, 2018.
21. Ito T, Hashimoto Y, Tanaka Y, et al. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naive essential thrombocythemia patients in a real-world setting. Eur J Haematol 103: 116-123, 2019.
22. Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens 29: 1270-1280, 2011.
23. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92: 69-76, 1992.
24. Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica 89: 1394-1395, 2004.
25. Engel PJ, Johnson H, Baughman RP, Richards AI. High-output heart failure associated with anagrelide therapy for essential thrombocytosis. Ann Intern Med 143: 311-313, 2005.
26. Wong RS, Lam LW, Cheng G. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Ann Hematol 87: 683-684, 2008.
27. Dziewierz A, Olszanecka A, Wilinski J, et al. Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine. Int J Cardiol 160: e31-e32, 2012.
28. Lee SH, Kim YS. Reversible dilated cardiomyopathy associated with long-term anagrelide therapy in a patient with chronic myeloproliferative disease: a serial 2-dimensional speckle tracking echocardiographic study. Int J Cardiol 173: e45-e46, 2014.
29. Singh P. A case of anagrelide-induced nonischemic cardiomyopathy in a patient with essential thrombocythemia. J Pharm Pract 31: 230-233, 2018.
30. Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 134: e32-e69, 2016.
31. Okamoto S, Miyakawa Y, Smith J, et al. Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia. Int J Hematol 97: 360-368, 2013.